The University of Cambridge and AstraZeneca have a long history of scientific collaboration. In 2013, AstraZeneca’s decision to move its global headquarters and new strategic R&D centre to Cambridge started a new chapter of partnership.
AstraZeneca chose Cambridge – the largest life science cluster in Europe – for its access to world-leading academic, industry and healthcare organisations, including the University of Cambridge.
Over the last decade, our partnership has gone from strength-to-strength, based on a shared ambition to drive progress for patients and society.
"Through our partnerships, we are:
Accelerating scientific discoveries into meaningful progress for patients.
Nurturing the next generation of talent that will lead the breakthroughs of the future.
And supporting initiatives to unlock the full potential of theCambridge innovation ecosystem."
Shaun Grady, Chair of AstraZeneca UK
Driving breakthroughs in science and innovation
"Why Cambridge? Because science advances through collaboration. Moving to this world-renowned bioscience hotspot means we have leading-edge academic and industry networks and scientific talent on our doorstep. We can see how sharing expertise and resources is driving progress for patients."
Steve Rees, Senior Vice-President, Discovery Sciences, R&D, AstraZeneca